New Age Alpha Advisors LLC Takes Position in Artivion, Inc. (NYSE:AORT)

New Age Alpha Advisors LLC acquired a new position in Artivion, Inc. (NYSE:AORT) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 52,223 shares of the company’s stock, valued at approximately $1,493,000. New Age Alpha Advisors LLC owned about 0.12% of Artivion at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Quarry LP increased its stake in shares of Artivion by 210.8% in the 3rd quarter. Quarry LP now owns 1,209 shares of the company’s stock valued at $32,000 after buying an additional 820 shares during the period. Smartleaf Asset Management LLC boosted its holdings in Artivion by 236.7% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,118 shares of the company’s stock valued at $32,000 after acquiring an additional 786 shares during the last quarter. R Squared Ltd acquired a new stake in Artivion in the fourth quarter worth about $39,000. Arcadia Investment Management Corp MI bought a new stake in Artivion during the 4th quarter worth about $43,000. Finally, Venturi Wealth Management LLC acquired a new position in Artivion during the 4th quarter valued at about $78,000. Institutional investors own 86.37% of the company’s stock.

Insider Buying and Selling

In other Artivion news, insider John E. Davis sold 15,100 shares of the stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $23.61, for a total transaction of $356,511.00. Following the completion of the transaction, the insider now owns 208,778 shares in the company, valued at approximately $4,929,248.58. This represents a 6.74 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Jean F. Holloway sold 18,020 shares of Artivion stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $23.61, for a total value of $425,452.20. Following the completion of the sale, the senior vice president now directly owns 197,184 shares in the company, valued at $4,655,514.24. This represents a 8.37 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 90,799 shares of company stock valued at $2,356,223. 8.10% of the stock is owned by corporate insiders.

Artivion Trading Down 1.0 %

AORT opened at $24.26 on Monday. Artivion, Inc. has a twelve month low of $19.36 and a twelve month high of $32.33. The firm has a market cap of $1.02 billion, a PE ratio of -1,212.80 and a beta of 1.79. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.33 and a current ratio of 1.88. The firm’s fifty day moving average is $27.58 and its two-hundred day moving average is $27.65.

Artivion (NYSE:AORT) last posted its earnings results on Monday, February 24th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of $0.12 by ($0.51). The business had revenue of $97.31 million for the quarter, compared to the consensus estimate of $100.82 million. Artivion had a positive return on equity of 5.15% and a negative net margin of 0.22%. Equities research analysts anticipate that Artivion, Inc. will post 0.37 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on AORT. Stifel Nicolaus lowered their price target on shares of Artivion from $33.00 to $30.00 and set a “buy” rating for the company in a research report on Tuesday, February 25th. Needham & Company LLC lowered their target price on shares of Artivion from $34.00 to $32.00 and set a “buy” rating for the company in a report on Tuesday, February 25th. Finally, JMP Securities reissued a “market outperform” rating and issued a $33.00 price target on shares of Artivion in a research note on Tuesday, December 10th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $31.40.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.